CNSX:LOVE

Stock Analysis Report

Executive Summary

Cannara Biotech Inc. operates indoor cannabis cultivation facility in Canada.

Snowflake

Fundamentals

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Cannara Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.0%

LOVE

2.6%

CA Pharmaceuticals

-0.2%

CA Market


1 Year Return

n/a

LOVE

-55.5%

CA Pharmaceuticals

1.1%

CA Market

Return vs Industry: Insufficient data to determine how LOVE performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LOVE performed against the Canadian Market.


Shareholder returns

LOVEIndustryMarket
7 Day3.0%2.6%-0.2%
30 Day0%-20.3%-3.3%
90 Day6.3%-32.9%-1.6%
1 Yearn/a-55.5%-55.5%4.6%1.1%
3 Yearn/a78.9%77.6%13.1%3.1%
5 Yearn/a287.4%287.4%24.7%6.7%

Price Volatility Vs. Market

How volatile is Cannara Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cannara Biotech undervalued compared to its fair value and its price relative to the market?

5.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LOVE is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate LOVE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LOVE is overvalued based on its PB Ratio (5.5x) compared to the CA Pharmaceuticals industry average (1.9x).


Next Steps

Future Growth

How is Cannara Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

86.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cannara Biotech performed over the past 5 years?

14.1%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if LOVE's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare LOVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LOVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: LOVE has a negative Return on Equity (-28.66%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: LOVE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LOVE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Cannara Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: LOVE's short term assets (CA$13.5M) exceeds its short term liabilities (CA$1.2M)

Long Term Liabilities: LOVE's short term assets (13.5M) exceeds its long term liabilities (13.0M)


Debt to Equity History and Analysis

Debt Level: LOVE's debt to equity ratio (84.8%) is considered high

Reducing Debt: Insufficient data to determine if LOVE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: LOVE has a high level of physical assets or inventory.

Debt Coverage by Assets: LOVE's debt is covered by short term assets (assets are 1.078020x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if LOVE has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LOVE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cannara Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LOVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LOVE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LOVE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Cannara Biotech's salary, the management and board of directors tenure and is there insider trading?


CEO

Zohar Krivorot (42yo)

0yrs

Tenure

0

Mr. Zohar Krivorot is Founder, President, Chief Executive Officer and Director at Cannara Biotech Inc. A successful entrepreneur, Mr. Krivorot has founded, advised, invested and sold numerous companies, in ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$18,91415 Aug 19
Javaa Private Equity Inc
EntityCompany
Shares125,000
Max PriceCA$0.15
BuyCA$62,20309 Aug 19
Javaa Private Equity Inc
EntityCompany
Shares422,000
Max PriceCA$0.15
BuyCA$47,30008 Aug 19
Javaa Private Equity Inc
EntityCompany
Shares345,000
Max PriceCA$0.14
BuyCA$8,10014 Mar 19
Lennie Ryer
EntityIndividual
Role
Chief Financial Officer
VP of Finance & CFO
Shares45,000
Max PriceCA$0.18
BuyCA$238,32414 Mar 19
Javaa Private Equity Inc
EntityCompany
Shares1,282,000
Max PriceCA$0.19
SellCA$98,50031 Jan 19
Donal Carroll
EntityIndividual
Shares500,000
Max PriceCA$0.20

Ownership Breakdown


Management Team

  • Lennie Ryer (58yo)

    VP of Finance & CFO

    • Tenure: 1.3yrs
    • Compensation: CA$300.00k
  • Zohar Krivorot (42yo)

    Founder

    • Tenure: 0yrs
  • Julia Bouvet

    Chief of Staff

    • Tenure: 0yrs
  • Barry Laxer

    Chief Operating Officer

    • Tenure: 0.2yrs

Board Members

  • Jack Kay (79yo)

    Director

    • Tenure: 0.5yrs
  • Amy Satov (50yo)

    Director

    • Tenure: 0yrs
  • Thomas Fairfull (70yo)

    Director

    • Tenure: 0yrs
  • Zohar Krivorot (42yo)

    Founder

    • Tenure: 0yrs
  • Derek Stern (52yo)

    Director

    • Tenure: 0yrs
  • Sara May

    Director

    • Tenure: 0.4yrs

Company Information

Cannara Biotech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cannara Biotech Inc.
  • Ticker: LOVE
  • Exchange: CNSX
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$120.151m
  • Shares outstanding: 706.77m
  • Website: https://cannara.ca

Number of Employees


Location

  • Cannara Biotech Inc.
  • 333 Decarie boulevard
  • Suite 200
  • St-Laurent
  • Quebec
  • H4N 3M9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LOVECNSX (Canadian National Stock Exchange)YesCommon SharesCACADJan 2019
LOVF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2019
8CBDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2019

Biography

Cannara Biotech Inc. operates indoor cannabis cultivation facility in Canada. The company was founded in 2018 and is headquartered in St-Laurent, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:35
End of Day Share Price2019/10/18 00:00
Earnings2018/08/31
Annual Earnings2018/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.